The Special District Foundation, Jeonbuk National University Hospital and the Korea Food Research Institute sign MOU to pool research, clinical and commercialization capabilities

Yang Jong-cheol (from left), president of Jeonbuk National University Hospital, Jung Hee-kwon, chairman of the Special District Foundation, and Baek Hyeon-dong, president of the Korea Food Research Institute, pose for a photo at the MOU signing ceremony. [Special District Foundation]
Yang Jong-cheol (from left), president of Jeonbuk National University Hospital, Jung Hee-kwon, chairman of the Special District Foundation, and Baek Hyeon-dong, president of the Korea Food Research Institute, pose for a photo at the MOU signing ceremony. [Special District Foundation]

A full-cycle technology commercialization system is being established to validate advanced biotech developed by research institutions at hospitals and connect it to companies for market entry.

The Special District Foundation signed an MOU with Jeonbuk National University Hospital and the Korea Food Research Institute on Wednesday at the Jeonbuk Tech-Biz Center to build a cooperative framework for commercializing advanced biotech.

At the heart of the agreement is linking the three institutions' respective capabilities in R&D, clinical validation and technology commercialization into a single pipeline — ensuring that research outcomes move beyond academic papers and patents to become actual products and business growth.

Jeonbuk National University Hospital will identify joint research projects based on clinical demand and take charge of designing and validating preclinical and clinical studies. It will also provide technology consulting using medical data, help secure regulatory approval evidence, and support market expansion through its hospital network.

The Korea Food Research Institute will identify promising technologies in advanced biotech and food, and handle follow-on R&D, technology upgrading and process improvement. Its support will span functional and safety evaluations, product formulation and standardization, and regulatory and commercialization consulting.

The Special District Foundation will connect public research outputs from 19 special R&D districts nationwide with corporate demand. It will support the entire commercialization process — from technology identification, valuation and transfer to follow-on R&D, pilot testing, regulatory response, prototype development, investment, market access and entry into domestic and overseas markets.

Building on the MOU, the three institutions plan to establish an advanced biotech cooperation network involving researchers and jointly identify and plan R&D projects. They will also work to match promising technologies with companies that need them.

The aim is to leverage North Jeolla Province's medical and research infrastructure as a hub for advanced biotech commercialization. Rather than limiting the effort to the region, the institutions plan to connect technologies and companies from special R&D districts across the country with North Jeolla's medical and research infrastructure to expand commercialization outcomes.

"This will be an opportunity for North Jeolla's core research and medical capabilities to translate into commercialization results in the advanced biotech sector," Special District Foundation Chairman Jung Hee-kwon said. "We will actively work to connect and expand regional innovation resources so that special districts can become an innovation platform that creates new growth engines for South Korea."


nbgkoo@heraldcorp.com